Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy
Stephanie Anderson, Anja Karlstaedt, Megan Young, Loucia Karatzia, Fenn Cullen, Jianmin Chen, Caroline E. O’Riordan, Michael R. Barnes, Zorana Štaka, Lauren J. Albee, Conor Garrod-Ketchley, Sanushi Dambure, Hiran A. Prag, Filip Cvetko, Jack J. J. J. Miller, , Dunja Aksentijević
In db/db mice, six weeks of AZD1656 improved diastolic function, cardiac metabolism and infarct size, with increased Treg infiltration and less fibrosis, without glycaemic change.
Nature Cardiovascular Research · Feb 23, 2026Peer-reviewedPhysiology✦ In-depth digest